Brain natriuretic peptide for prediction of mortality in patients with sepsis: A systematic review and meta-analysis

Critical Care

Volumn 16, Issue 3, 2012, Pages

  Wang, Fei ^a   Wu, Youping ^a   Tang, Lu ^a,b   Zhu, Weimin ^a   Chen, Feng ^a   Xu, Tao ^a   Bo, Lulong ^a   Li, Jinbao ^a   Deng, Xiaoming ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

^b JINAN MILITARY GENERAL HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BRAIN NATRIURETIC PEPTIDE; BIOLOGICAL MARKER;

ARTICLE; COCHRANE LIBRARY; EMBASE; HUMAN; MEDLINE; META ANALYSIS; MORTALITY; PREDICTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; SENSITIVITY AND SPECIFICITY; SEPSIS; SYSTEMATIC REVIEW; VALIDITY; BLOOD; CLINICAL TRIAL (TOPIC); PREDICTIVE VALUE; PROCEDURES; TRENDS;

BIOLOGICAL MARKERS; CLINICAL TRIALS AS TOPIC; HUMANS; MORTALITY; NATRIURETIC PEPTIDE, BRAIN; PREDICTIVE VALUE OF TESTS; SEPSIS;

EID: 84860518979     PISSN: 13648535     EISSN: 1466609X     Source Type: Journal    
DOI: 10.1186/cc11331     Document Type: Article

References (51)

1. Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 2001, 29:1303-1310. 10.1097/00003246-200107000-00002, 11445675.
2. Gullo A, Bianco N, Berlot G. Management of severe sepsis and septic shock: challenges and recommendations. Crit Care Clin 2006, 22:489-501. 10.1016/j.ccc.2006.03.006, 16893735.
3. Hotchkiss RS, Karl IE. The pathophysiology and treatment of sepsis. N Engl J Med 2003, 348:138-150. 10.1056/NEJMra021333, 12519925.
4. Kumar A, Roberts D, Wood KE, Light B, Parrillo JE, Sharma S, Suppes R, Feinstein D, Zanotti S, Taiberg L, Gurka D, Kumar A, Cheanq M. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med 2006, 34:1589-1596. 10.1097/01.CCM.0000217961.75225.E9, 16625125.
5. Rangel-Frausto MS, Pittet D, Costigan M, Hwang T, Davis CS, Wenzel RP. The natural history of the systemic inflammatory response syndrome (SIRS). A prospective study. JAMA 1995, 273:117-123. 10.1001/jama.1995.03520260039030, 7799491.
6. Zambon M, Ceola M, Almeida-de-Castro R, Gullo A, Vincent JL. Implementation of the Surviving Sepsis Campaign guidelines for severe sepsis and septic shock: we could go faster. J Crit Care 2008, 23:455-460. 10.1016/j.jcrc.2007.08.003, 19056006.
7. Levin ER, Gardner DG, Samson WK. Natriuretic peptides. N Engl J Med 1998, 339:321-328. 10.1056/NEJM199807303390507, 9682046.
8. Goetze JP, Christoffersen C, Perko M, Arendrup H, Rehfeld JF, Kastrup J, Nielsen LB. Increased cardiac BNP expression associated with myocardial ischemia. FASEB J 2003, 17:1105-1107.
9. Vanderheyden M, Bartunek J, Goethals M. Brain and other natriuretic peptides: molecular aspects. Eur J Heart Fail 2004, 6:261-268. 10.1016/j.ejheart.2004.01.004, 14987574.
10. Tang WH, Francis GS, Morrow DA, Newby LK, Cannon CP, Jesse RL, Storrow AB, Christenson RH, Apple FS, Ravkilde J, Wu AH, . National Academy of Clinical Biochemistry Laboratory Medicine National Academy of Clinical Biochemistry Laboratory Medicine practice guidelines: Clinical utilization of cardiac biomarker testing in heart failure. Circulation 2007, 116:e99-109. 10.1161/CIRCULATIONAHA.107.185267, 17630410, National Academy of Clinical Biochemistry Laboratory Medicine.
11. Kragelund C, Gronning B, Kober L, Hildebrandt P, Steffensen R. N-terminal pro-B-type natriuretic peptide and long-term mortality in stable coronary heart disease. N Engl J Med 2005, 352:666-675. 10.1056/NEJMoa042330, 15716560.
12. De Lemos JA, Morrow DA, Bentley JH, Omland T, Sabatine MS, McCabe CH, Hall C, Cannon CP, Braunwald E. The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes. N Engl J Med 2001, 345:1014-1021. 10.1056/NEJMoa011053, 11586953.
13. Pieralli F, Olivotto I, Vanni S, Conti A, Camaiti A, Targioni G, Grifoni S, Berni G. Usefulness of bedside testing for brain natriuretic peptide to identify right ventricular dysfunction and outcome in normotensive patients with acute pulmonary embolism. Am J Cardiol 2006, 97:1386-1390. 10.1016/j.amjcard.2005.11.075, 16635617.
14. Karthikeyan G, Moncur RA, Levine O, Heels-Ansdell D, Chan MT, Alonso-Coello P, Yusuf S, Sessler D, Villar JC, Berwanger O, McQueen M, Mathew A, Hill S, Gibson S, Berry C, Yeh HM, Devereaux PJ. Is a pre-operative brain natriuretic peptide or N-terminal pro-B-type natriuretic peptide measurement an independent predictor of adverse cardiovascular outcomes within 30 days of noncardiac surgery? A systematic review and meta-analysis of observational studies. J Am Coll Cardiol 2009, 54:1599-1606. 10.1016/j.jacc.2009.06.028, 19833258.
15. Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, Moher D, Becker BJ, Sipe TA, Thacker SB. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA 2000, 283:2008-2012. 10.1001/jama.283.15.2008, 10789670.
16. Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics 1977, 33:159-174. 10.2307/2529310, 843571.
17. Whiting P, Rutjes AW, Reitsma JB, Bossuyt PM, Kleijnen J. The development of QUADAS: a tool for the quality assessment of studies of diagnostic accuracy included in systematic reviews. BMC Med Res Methodol 2003, 3:25. 10.1186/1471-2288-3-25, 305345, 14606960.
18. Zamora J, Abraira V, Muriel A, Khan K, Coomarasamy A. Meta-DiSc: a software for meta-analysis of test accuracy data. BMC Med Res Methodol 2006, 6:31. 10.1186/1471-2288-6-31, 1552081, 16836745.
19. Deville WL, Buntinx F, Bouter LM, Montori VM, de Vet HC, van der Windt DA, Bezemer PD. Conducting systematic reviews of diagnostic studies: didactic guidelines. BMC Med Res Methodol 2002, 2:9. 10.1186/1471-2288-2-9, 117243, 12097142.
20. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986, 7:177-188. 10.1016/0197-2456(86)90046-2, 3802833.
21. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003, 327:557-560. 10.1136/bmj.327.7414.557, 192859, 12958120.
22. Perman SM, Chang AM, Hollander JE, Gaieski DF, Trzeciak S, Birkhahn R, Otero R, Osborn TM, Moretti E, Nguyen HB, Gunnerson KJ, Milzman D, Goyal M, Cairns CB, Ngo L, Rivers EP, Shapiro NI. Relationship between B-type natriuretic peptide and adverse outcome in patients with clinical evidence of sepsis presenting to the emergency department. Acad Emerg Med 2011, 18:219-222.
23. Sturgess DJ, Marwick TH, Joyce C, Jenkins C, Jones M, Masci P, Stewart D, Venkatesh B. Prediction of hospital outcome in septic shock: a prospective comparison of tissue Doppler and cardiac biomarkers. Crit Care 2010, 14:R44. 10.1186/cc8931, 2887156, 20331902.
24. Zhao HY, An YZ, Liu F. Prognostic values of B-type natriuretic peptide in severe sepsis and septic shock. Zhongguo Wei Zhong Bing Ji Jiu Yi Xue 2009, 21:293-295.
25. Chen Y, Li C. Prognostic significance of brain natriuretic peptide obtained in the ED in patients with SIRS or sepsis. Am J Emerg Med 2009, 27:701-706. 10.1016/j.ajem.2009.02.001, 19751627.
26. Yucel T, Memis D, Karamanlioglu B, Süt N, Yuksel M. The prognostic value of atrial and brain natriuretic peptides, troponin I and C-reactive protein in patients with sepsis. Exp Clin Cardiol 2008, 13:183-188. 2663482, 19343164.
27. Post F, Weilemann LS, Messow CM, Sinning C, Münzel T. B-type natriuretic peptide as a marker for sepsis-induced myocardial depression in intensive care patients. Crit Care Med 2008, 36:3030-3037. 10.1097/CCM.0b013e31818b9153, 18824903.
28. Varpula M, Pulkki K, Karlsson S, Ruokonen E, Pettilä V, . FINNSEPSIS Study Group Predictive value of N-terminal pro-brain natriuretic peptide in severe sepsis and septic shock. Crit Care Med 2007, 35:1277-1283. 10.1097/01.CCM.0000261893.72811.0F, 17414731, FINNSEPSIS Study Group.
29. Mokart D, Sannini A, Brun JP, Faucher M, Blaise D, Blache JL, Faucher C. N-terminal pro-brain natriuretic peptide as an early prognostic factor in cancer patients developing septic shock. Crit Care 2007, 11:R37. 10.1186/cc5721, 2206454, 17359530.
30. Ueda S, Nishio K, Akai Y, Fukushima H, Ueyama T, Kawai Y, Masui K, Yoshioka A, Okuchi K. Prognostic value of increased plasma levels of brain natriuretic peptide in patients with septic shock. Shock 2006, 26:134-139. 10.1097/01.shk.0000226266.99960.d0, 16878020.
31. Roch A, Allardet-Servent J, Michelet P, Oddoze C, Forel JM, Barrau K, Loundou A, Perrin G, Auffray JP, Portugal H, Papazian L. NH2 terminal pro-brain natriuretic peptide plasma level as an early marker of prognosis and cardiac dysfunction in septic shock patients. Crit Care Med 2005, 33:1001-1007. 10.1097/01.CCM.0000162561.82012.E9, 15891328.
32. Brueckmann M, Huhle G, Lang S, Haase KK, Bertsch T, Weiss C, Kaden JJ, Putensen C, Borggrefe M, Hoffmann U. Prognostic value of plasma N-terminal pro-brain natriuretic peptide in patients with severe sepsis. Circulation 2005, 112:527-534. 10.1161/CIRCULATIONAHA.104.472050, 16027260.
33. Charpentier J, Luyt CE, Fulla Y, Vinsonneau C, Cariou A, Grabar S, Dhainaut JF, Mira JP, Chiche JD. Brain natriuretic peptide: A marker of myocardial dysfunction and prognosis during severe sepsis. Crit Care Med 2004, 32:660-665. 10.1097/01.CCM.0000114827.93410.D8, 15090944.
34. Maeder M, Ammann P, Kiowski W, Rickli H. B-type natriuretic peptide in patients with sepsis and preserved left ventricular ejection fraction. Eur J Heart Fail 2005, 7:1164-1167. 10.1016/j.ejheart.2005.03.003, 16202651.
35. Court O, Kumar A, Parrillo JE. Clinical review: Myocardial depression in sepsis and septic shock. Crit Care 2002, 6:500-508. 10.1186/cc1822, 153435, 12493071.
36. Tomaru Ki K, Arai M, Yokoyama T, Aihara Y, Sekiguchi Ki K, Tanaka T, Nagai R, Kurabayashi M. Transcriptional activation of the BNP gene by lipopolysaccharide is mediated through GATA elements in neonatal rat cardiac myocytes. J Mol Cell Cardiol 2002, 34:649-659. 10.1006/jmcc.2002.2005, 12054852.
37. He Q, LaPointe MC. Interleukin-1beta regulation of the human brain natriuretic peptide promoter involves Ras-, Rac-, and p38 kinase-dependent pathways in cardiac myocytes. Hypertension 1999, 33:283-289.
38. Kuwahara K, Saito Y, Harada M, Ishikawa M, Ogawa E, Miyamoto Y, Hamanaka I, Kamitani S, Kajiyama N, Takahashi N, Nakagawa O, Masuda I, Nakao K. Involvement of cardiotrophin-1 in cardiac myocyte-nonmyocyte interactions during hypertrophy of rat cardiac myocytes in vitro. Circulation 1999, 100:1116-1124.
39. Phua J, Lim TK, Lee KH. B-type natriuretic peptide: issues for the intensivist and pulmonologist. Crit Care Med 2005, 33:2094-2013. 10.1097/01.CCM.0000178351.03327.9F, 16148485.
40. Maeder M, Fehr T, Rickli H, Ammann P. Sepsis-associated myocardial dysfunction: diagnostic and prognostic impact of cardiac troponins and natriuretic peptides. Chest 2006, 129:1349-1366. 10.1378/chest.129.5.1349, 16685029.
41. Kandil E, Burack J, Sawas A, Bibawy H, Schwartzman A, Zenilman ME, Bluth MH. B-type natriuretic peptide: a biomarker for the diagnosis and risk stratification of patients with septic shock. Arch Surg 2008, 143:242-6. 10.1001/archsurg.2007.69, 18347270.
42. Rivers EP. Clinical Utility of B-Type Natriuretic Peptide in Early Severe Sepsis and Septic Shock. J Intensive Care Med 2007, 22:363-73. 10.1177/0885066607307523, 18051697.
43. Giamarellos-Bourboulis EJ, Tsangaris I, Kanni T, Mouktaroudi M, Pantelidou I, Adamis G, Atmatzidis S, Chrisofos M, Evangelopoulou V, Frantzeskaki F, Giannopoulos P, Giannikopoulos G, Gialvalis D, Gourgoulis GM, Kotzampassi K, Katsifa K, Kofinas G, Kontopidou F, Koratzanis G, Koulouras V, Koutsikou A, Koupetori M, Kritselis I, Leonidou L, Mega A, Mylona V, Nikolaou H, Orfanos S, Panagopoulos P, Paramythiotou E, , et al. Hellenic Sepsis Study Group Procalcitonin as an early indicator of outcome in sepsis: a prospective observational study. J Hosp Infect 2011, 77:58-63. 10.1016/j.jhin.2010.07.026, 21131099, Hellenic Sepsis Study Group.
44. Choon-ngarm T, Partpisanu P. Serum cardiac troponin-T as a prognostic marker in septic shock. J Med Assoc Thai 2008, 91:1818-1821.
45. Mehta NJ, Khan IA, Gupta V, Jani K, Gowda RM, Smith PR. Cardiac troponin I predicts myocardial dysfunction and adverse outcome in septic shock. Int J Cardiol 2004, 95:13-17. 10.1016/j.ijcard.2003.02.005, 15159032.
46. Pierrakos C, Vincent JL. Sepsis biomarkers: a review. Crit Care 2010, 14:R15. 10.1186/cc8872, 2875530, 20144219.
47. Omland T. Advances in congestive heart failure management in the intensive care unit: B-type natriuretic peptides in evaluation of acute heart failure. Crit Care Med 2008, 36:S17-27. 10.1097/01.CCM.0000296266.74913.85, 18158473.
48. Prontera C, Zaninotto M, Giovannini S, Zucchelli GC, Pilo A, Sciacovelli L, Plebani, Clerico A. Proficiency testing project for brain natriuretic peptide (BNP) and the N-terminal part of the propeptide of BNP (NT-proBNP) immunoassays: the CardioOrmocheck study. Clin Chem Lab Med 2009, 47:762-768.
49. Hoste EA, Lameire NH, Vanholder RC, Benoit DD, Decruyenaere JM, Colardyn FA. Acute renal failure in patients with sepsis in a surgical ICU: predictive factors, incidence, comorbidity, and outcome. J Am Soc Nephrol 2003, 14:1022-1030. 10.1097/01.ASN.0000059863.48590.E9, 12660337.
50. Yegenaga I, Hoste E, Van Biesen W, Vanholder R, Benoit D, Kantarci G, Dhondt A, Colardyn F, Lameire N. Clinical characteristics of patients developing ARF due to sepsis/systemic inflammatory response syndrome: Results of a prospective study. Am J Kidney Dis 2004, 43:817-824. 10.1053/j.ajkd.2003.12.045, 15112172.
51. Goei D, Schouten O, Boersma E, Welten GM, Dunkelgrun M, Lindemans J, van Gestel YR, Hoeks SE, Bax JJ, Poldermans D. Influence of renal function on the usefulness of N-terminal pro-B-type natriuretic peptide as a prognostic cardiac risk marker in patients undergoing noncardiac vascular surgery. Am J Cardiol 2008, 101:122-126. 10.1016/j.amjcard.2007.07.058, 18157978.